A majority of people have supported the urgent implentation of early screening for a genetic disease that causes severe muscle degeneration. The last Government promised to add the test for Spinal ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The family vehicle helps their teen daughter, who is in a wheelchair, drive more easily. Video from the car caught the act and the suspect’s license plate.

Treatment with Spinraza (nusinersen) can help stabilize or improve motor function in adults with SMA, according to a new ...

Neuromuscular diseases encompass a wide range of disorders characterized by progressive muscle weakness and dysfunction, resulting from abnormalities in the ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration FDA has accepted its Biologics License Application BLA for ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...